Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model
View abstract on PubMed
Summary
This summary is machine-generated.Macrophage activating lipopeptide 2 (MALP-2) immunotherapy showed a tumor suppressive effect in a pancreatic cancer mouse model. Combined with chemotherapy, MALP-2 significantly prolonged survival and enhanced anti-tumor immunity.
Area Of Science
- Immunology
- Oncology
- Molecular Biology
Background
- Pancreatic cancer exhibits a poor prognosis, necessitating novel therapeutic strategies like immunotherapy.
- Macrophage activating lipopeptide 2 (MALP-2) is a toll-like receptor 2 and 6 agonist with immunomodulatory properties.
- MALP-2 activates nuclear factor kappaB in monocytes, leading to chemokine and cytokine release.
Purpose Of The Study
- To investigate the immunomodulatory capacity and therapeutic potential of MALP-2 in pancreatic cancer.
- To evaluate the effect of MALP-2 on tumor growth, immune status, and immune cell infiltration in an orthotopic pancreatic cancer model.
Main Methods
- An orthotopic ultrasound-guided pancreatic cancer mouse model using Panc 02 cells in C57bl/6 mice was established.
- MALP-2 was administered intratumorally or intraperitoneally.
- Tumor growth, immune status, and leukocyte infiltration were assessed.
Main Results
- A single MALP-2 injection demonstrated a tumor suppressive effect, increasing median survival from 21 to 30 days.
- Combined MALP-2 and gemcitabine chemotherapy significantly prolonged survival (median 37 days vs. 27 days with chemotherapy alone).
- Treatment increased cytotoxic T cells, restored beta2 integrin on lymphocytes, upregulated CD45RB on T helper cells, and enhanced cytotoxic T lymphocyte and natural killer cell infiltration.
Conclusions
- Synthetic lipopeptide MALP-2 demonstrated a tumor suppressive effect in an orthotopic mouse model of pancreatic cancer.
- MALP-2 treatment holds potential as an immunotherapy option for pancreatic cancer.